Clinical Trial Detail

NCT ID NCT01218048
Title ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Pittsburgh
Indications

oropharynx cancer

head and neck cancer

oral cavity cancer

hypopharynx cancer

larynx cancer

Therapies

Cisplatin

Carboplatin

Cetuximab

Age Groups: adult

No variant requirements are available.